Evaluation of Sodium-Glucose Cotransporter-2 Inhibitor Use in an Underserved Ambulatory Care Population With Type 2 Diabetes

Abstract

Get full access to this article

View all access options for this article.

References

Trujillo

Nuffer

WA.

Impact of sodium-glucose cotransporter 2 inhibitors on nonglycemic outcomes in patients with type 2 diabetes. Pharmacotherapy. 2017;37(4):481-491.

Vallon

Thomson

SC.

Targeting renal glucose reabsorption to treat hyperglycemia: the pleiotropic effects of SGLT2 inhibition. Diabetologia. 2017;60(2):215-225.

Gale

Poon

Watson

Antihyperglycemic medications and impact on cardiovascular outcomes: a review of current evidence. Pharmacotherapy. 2018;38(7):739-757.

Neal

Perkovic

Mahaffey

,et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644-657.

Zinman

Wagner

Lachin

,et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117-2128.

Perkovic

Jardine

Neal

,et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;360(16):1-12.

Heerspink

Stefánsson

Correa-Rotter

,et al. on behalf of the DAPA-CKD Trial Committees and Investigators. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383:1436-1446.

Packer

Anker

Butler

,et al. on behalf of the EMPEROR-Reduced Trial Investigators. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383:1413-24.

FDA Drug Safety Communication. FDA strengthens kidney warnings for diabetes medicines canagliflozin (Invokana, Invokamet) and dapagliflozin (Farxiga, Xigduo XR). Accessed March 31, 2021. https://www.fda.gov/downloads/Drugs/DrugSafety/UCM506772.pdf

10.

Bersoff-Matcha

Chamberlain

Cao

Kortepeter

Chong

WH.

Fournier gangrene associated with sodium-glucose cotransporter-2 inhibitors: a review of spontaneous postmarketing cases. Ann Intern Med. 2019;170(11):764-769.

11.

Fitchett

A safety update on sodium glucose co-transporter 2 inhibitors. Diabetes Obes Metab. 2019;21(suppl 2):34-42.

12.

Taylor

Blau

Rother

KI.

SGLT2 inhibitors may predispose to ketoacidosis. J Clin Endocrinol Metab. 2015;100:2849-2852.

13.

Rosenstock

Ferrannini

Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors. Diabetes Care. 2015;38:1638-1642.

14.

Gomez-Peralta

Abreu

Lecube

,et al. Practical approach to initiating SGLT2 inhibitors in type 2 diabetes. Diabetes Ther. 2017;8:953-962.

15.

Product Information: Farxiga (dapagliflozin). AstraZeneca Pharmaceuticals LP. Wilmington, DE; 2020.

16.

Product Information: Invokana (canagliflozin). Janssen Pharmaceuticals, Inc. Titusville, NJ; 2020.

17.

Product Information: Jardiance (empagliflozin). Boehringer Ingelheim Pharmaceuticals. Inc .Ridgefield, CT; 2020.

18.

American Diabetes Association Clinical Practice Recommendations 2021. Diabetes Care. 2021;44(suppl 1):S1-232.

19.

Nauck

MA.

Update on developments with SGLT2 inhibitors in the management of type 2 diabetes. Drug Des Devel Ther. 2014;8:1335-1380.

20.

Nadkarni

Ferrandino

Change

,et al. Acute kidney injury in patients on SGLT2 inhibitors: a propensity-matched analysis. Diabetes Care. 2017;40(11):1479-1485.

21.

Liu

Jia

,et al. Effects of SGLT2 inhibitors on UTIs and genital infections in type 2 diabetes mellitus: a systematic review and meta-analysis. Sci Rep. 2017;7:2824.

22.

FDA Drug Safety Communication. FDA warns about rare occurrences of a serious infection of the genital area with SGLT2 inhibitors for diabetes. Accessed March 31, 2021. https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-about-rare-occurrences-serious-infection-genital-area-sglt2-inhibitors-diabetes

23.

FDA Drug Safety Communication. FDA confirms increased risk of leg and foot amputations with the diabetes medicine canagliflozin (Invokana, Invokamet, Invokamet XR). Accessed March 31, 2021. https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-confirms-increased-risk-leg-and-foot-amputations-diabetes-medicine

24.

Gordon

Clements

JN.

To heart “fail” or not? The expanding role of SGLT2 inhibitors. ADCES in Practice. 2021;9(2):28-33.

25.

Cook

Ayers

Sisson

EM.

SGLT2 inhibitors: cardiovascular benefits beyond glycemic control. AADE in Practice. 2018;6(3):34-39. doi:10.1177/2325160318762127

26.

McMurry

JJV

Solomon

Inzucchi

,et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. New Engl J Med. 2019;381:1995-2008.